Panorama Research Incorporated
Biotech · Private
Isthmin 1 (Ism1) therapeutic candidate with extended half-life to treat sarcopenia and preserve muscle mass
- Grants
- $12M
- 28 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20112013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Agriculture · Gratuitous Inducer For Industrial Enzyme Production | $98,739 | |
| Federal grant | Department of Agriculture · Scale-up Of Gratuitous Inducer For Industrial Enzyme Production | $449,621 | |
| Federal grant | Department of Health and Human Services · Phase I · Rational antibody therapy for IPF | $223,800 | |
| Federal grant | Department of Health and Human Services · Phase I · Rational antibody therapy for IPF | $223,800 | |
| Federal grant | Department of Health and Human Services · Phase I · Neutralization of Fibrosis-promoting Marinobufagenin for Diabetic Nephropathy | $224,779 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Monoclonal antibody for autoimmune disease | $224,981 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Antibody-Membrane Switch (AMS) technology for optimized antibody engineering | $499,789 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for Netherton syndrome | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel NMDA Receptor Antagonists for Beta Cell Rescue | $224,620 | |
| Federal grant | Department of Health and Human Services · Phase II · Antibody-Membrane Switch (AMS) technology for optimized antibody engineering | $455,800 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Aminoadamantane Nitrates for the Treatment of Neurological Diseases | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Anti-inflammmatory Antibody Therapy for Inflammatory Bowel Disease | $224,665 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Anti-inflammmatory Antibody Therapy for Inflammatory Bowel Disease | $224,665 | |
| Federal grant | Department of Health and Human Services · Phase I · Hepcidin Antagonist Therapy for Anemia of Chronic Disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Hepcidin Antagonist Therapy for Anemia of Chronic Disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for erosive bone disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for erosive bone disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase II · Rational antibody therapy for IPF | $1,493,613 | |
| Federal grant | Department of Health and Human Services · Phase II · Rational antibody therapy for IPF | $735,251 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel NMDA-targeted Therapy for Alzheimer's Disease | $788,076 | |
| Federal grant | Department of Health and Human Services · Phase II · Monoclonal antibody for autoimmune disease | $592,822 | |
| Federal grant | Department of Health and Human Services · Phase II · Rational antibody therapy for IPF | $758,362 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel NMDA-targeted Therapy for Alzheimer's Disease | $710,940 | |
| Federal grant | Department of Health and Human Services · Phase II · Monoclonal antibody for autoimmune disease | $905,412 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia | $299,989 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for arthrofibrosis | $275,765 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy to prevent alveolar bone loss in severe periodontitis | $304,019 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapy for Sarcopenia | $354,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3041 | DISCOVERY GENOMICS, INC. | — | — |
| 3042 | TOPOGENE, INC. | — | — |
| 3043 | AIVOCODE, INC. | — | — |
| 3044 | Panorama Research Incorporated | — | — |
| 3045 | E&E BIOCLUB LLC | — | — |
| 3046 | VIRONIKA LLC | — | — |
| 3047 | CASCADE THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.